In 2010 Weiss et al. were the first to describe frequent fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell cancer (SCC) of the lung. The FGFR1 amplification was detected in an unbiased approach using SNP (Single Nucleotide Polymorphisms) arrays on a large cohort of patients with SCC of the lung (n=155) and was validated in an independent cohort (n=153) by fluorescence in-situ hybridization (FISH) with a frequency of 22%. Weiss et al. were also able to show growth inhibition of FGFR1 amplified cell lines in vitro and in vivo using the FGFR inhibitor PD173074. The FGFR1 amplification rate described by Weiss et al. for SCC of the lung was confirmed by Dutt et al. shortly afterwards. In a follow-up study, we detected the occurrence of FGFR1 amplification not only at a similar frequency in primary SCCs of the lung but also in the corresponding regional lymph node metastases of FGFR1 amplified primary tumors, suggesting a clonal event in tumor progression. Our findings provide a rationale for treating patients with advanced disease with FGFR small molecule inhibitors and suggest that biopsy of the metastases would be adequate for determining the FGFR1 status of the primary tumor and vice versa.
Drug targets for cancer: FGFR1 research reagents
Other vital drug targets for cancer likeFGFR1:
Heist R S, Mino-Kenudson M, Sequist L V, et al. FGFR1 amplification in squamous cell carcinoma of the lung[J]. Journal of Thoracic Oncology, 2012, 7(12): 1775-1780.
von M?ssenhausen A, Franzen A, Heasley L, et al. FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area[J]. Annals of translational medicine, 2013, 1(3).